Skip to main content

Vertex: Did Management Deliver Investors a Backhanded Slap?

Leerink analyst Geoffrey Porges took Vertex Pharmaceuticals (VRTX) to the woodshed today over sales of its cystic fibrosis drug Orkambi . But he still sees the stock outperforming over the next 12 months.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.